NASDAQ:AGRX - Agile Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.38 -0.03 (-2.13 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$1.38
Today's Range$1.31 - $1.41
52-Week Range$0.23 - $3.00
Volume220,630 shs
Average Volume509,704 shs
Market Capitalization$59.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.47
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGRX
CUSIPN/A
Phone609-683-1880

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.59 per share

Profitability

Net Income$-19,780,000.00

Miscellaneous

Employees13
Market Cap$59.64 million
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics Inc (NASDAQ:AGRX) posted its earnings results on Tuesday, March, 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. View Agile Therapeutics' Earnings History.

When is Agile Therapeutics' next earnings date?

Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Agile Therapeutics.

What price target have analysts set for AGRX?

4 analysts have issued twelve-month price objectives for Agile Therapeutics' stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Agile Therapeutics' stock price to reach $3.50 in the next year. This suggests a possible upside of 153.6% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.

What is the consensus analysts' recommendation for Agile Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.

What are Wall Street analysts saying about Agile Therapeutics stock?

Here are some recent quotes from research analysts about Agile Therapeutics stock:
  • 1. Maxim Group analysts commented, "Agile Therapeutics announced topline results from its comparative adhesion wear study of Twirla vs. Xulane (generic Otho-Evra). Twirla met its primary endpoint of non-inferiority to Xulane, which the FDA considers to have acceptable adhesion for a patch contraceptive. These results will be used to answer FDA adhesion questions from the 2017 CRL and will be included in the NDA package." (2/11/2019)
  • 2. HC Wainwright analysts commented, "We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research." (1/11/2019)

Has Agile Therapeutics been receiving favorable news coverage?

News stories about AGRX stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Agile Therapeutics earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of Agile Therapeutics' key competitors?

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include Ultra Clean (UCTT), Mattel (MAT), General Electric (GE), AcelRx Pharmaceuticals (ACRX), American National BankShares (AMNB), US Foods (USFD), Enterprise Bancorp (EBTC), Opko Health (OPK), Twitter (TWTR) and Alibaba Group (BABA).

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the folowing people:
  • Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
  • Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
  • Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
  • Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
  • Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $1.38.

How big of a company is Agile Therapeutics?

Agile Therapeutics has a market capitalization of $59.64 million. The specialty pharmaceutical company earns $-19,780,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe.

What is Agile Therapeutics' official website?

The official website for Agile Therapeutics is http://www.agiletherapeutics.com.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]


MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel